The administration of the PAM of the mGlu5 receptor CDPPB in the olfactory bulbectomized rat model, a well-established model of depression and Alzheimer’s disease, ameliorated cognitive impairment and partially reversed the changes in eNOS and nNOS brain expression induced by the lesion [45]. This evidence concerns the gene NOS1 and early-onset autosomal dominant Alzheimer disease.